Literature DB >> 16214073

Evaluation of depression and anxiety in patients with systemic sclerosis.

Cécile Legendre1, Yannick Allanore, Isabelle Ferrand, André Kahan.   

Abstract

OBJECTIVE: To determine the prevalence of depression and anxiety in patients receiving follow-up in France for systemic sclerosis. PATIENTS: We prospectively evaluated 42 patients admitted for a follow-up evaluation of systemic sclerosis, including 18 with diffuse cutaneous scleroderma and 24 with limited cutaneous scleroderma. Patients admitted for recent organ involvement were excluded. Mean age was 57 +/- 13 years, mean disease duration was 10.2 +/- 8 years, and the mean functional Health Assessment Questionnaire score was 0.682 +/- 0.649. Only four patients had a history of antidepressive drug therapy. We used the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale to evaluate depression and anxiety, respectively.
RESULTS: Eighteen (43%) patients met criteria for depression and 11 (26%) had scores above the cutoff usually taken to define moderate-to-severe depression. Twenty-seven (64%) patients met criteria for minor anxiety and eight (19%) for major anxiety. Depression and anxiety were strongly correlated with each other (r = 0.89; P < 0.0001). The MADRS score was significantly higher in the patients with pulmonary restrictive disease (P = 0.009) but was not associated with the extent of skin involvement, organ involvement, or disability.
CONCLUSION: Systemic scleroderma is associated with a high prevalence of depression and anxiety. These disorders should be looked for routinely and the need for specific treatment evaluated.

Entities:  

Mesh:

Year:  2005        PMID: 16214073     DOI: 10.1016/j.jbspin.2003.11.008

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  17 in total

Review 1.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

2.  New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN).

Authors:  Brett D Thombs; Lisa R Jewett; Shervin Assassi; Murray Baron; Susan J Bartlett; Angela Costa Maia; Ghassan El-Baalbaki; Daniel E Furst; Karen Gottesman; Jennifer A Haythornthwaite; Marie Hudson; Ann Impens; Annett Korner; Catarina Leite; Maureen D Mayes; Vanessa L Malcarne; Sarosh J Motivala; Luc Mouthon; Warren R Nielson; Diane Plante; Serge Poiraudeau; Janet L Poole; Janet Pope; Maureen Sauve; Russell J Steele; Maria E Suarez-Almazor; Suzanne Taillefer; Cornelia H van den Ende; Erin Arthurs; Marielle Bassel; Vanessa Delisle; Katherine Milette; Allison Leavens; Ilya Razykov; Dinesh Khanna
Journal:  Clin Exp Rheumatol       Date:  2012-05-29       Impact factor: 4.473

3.  Depression among the Moroccan systemic sclerosis.

Authors:  Fahd Wafki; Bouchra Amine; Yousra Ibn Yacoub; Assia Laatiriss; Fatima Znat; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-06-01       Impact factor: 2.980

Review 4.  Negative affect in systemic sclerosis.

Authors:  Leticia Leon; Lydia Abasolo; Marta Redondo; Miguel Angel Perez-Nieto; Luis Rodriguez-Rodriguez; Maria Isabel Casado; Rafael Curbelo; Juan Angel Jover
Journal:  Rheumatol Int       Date:  2013-09-27       Impact factor: 2.631

5.  Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis.

Authors:  Christine March; Dörte Huscher; Emelina Preis; Alexander Makowka; Jakob Hoeppner; Frank Buttgereit; Gabriela Riemekasten; Kristina Norman; Elise Siegert
Journal:  Arch Rheumatol       Date:  2019-01-28       Impact factor: 1.472

Review 6.  Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Authors:  Eleni Pagkopoulou; Alexandra Arvanitaki; Dimitrios Daoussis; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2019-07-12       Impact factor: 2.631

7.  The impact of depression, microvasculopathy, and fibrosis on development of erectile dysfunction in men with systemic sclerosis.

Authors:  Predrag Ostojic; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2007-02-10       Impact factor: 2.980

8.  Measuring illness behavior in patients with systemic sclerosis.

Authors:  Erin L Merz; Vanessa L Malcarne; Scott C Roesch; Roozbeh Sharif; Brock E Harper; Hilda T Draeger; Emilio B Gonzalez; Deepthi K Nair; Terry A McNearney; Shervin Assassi; Maureen D Mayes
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

9.  [Medico-legal assessment of systemic sclerosis].

Authors:  M Graninger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

10.  Biopsychosocial typologies of pain in a cohort of patients with systemic sclerosis.

Authors:  Erin L Merz; Vanessa L Malcarne; Shervin Assassi; Deepthi K Nair; Tiffany A Graham; Brayden P Yellman; Rosa M Estrada-Y-Martin; Maureen D Mayes
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.